PHOTO
United Arab Emirates : The Biosynex group will be present this year at Arab Health 2022 exhibition. The company, which specializes in the design of medical devices, will present innovative solutions to fight COVID-19 epidemic. Biosynex will present during the show two innovative devices that simplify the diagnosis of SARS-CoV-2: AMPLIQUICK® and LABPAD® Evolution.
The first, BIOSYNEX AMPLIQUICK® enables the detection by RT-PCR of 4 major respiratory viruses. This amplification kit eliminates the extraction step, thus reducing the number of handling operations and saving laboratory technicians valuable time. The AMPLIQUICK® device also enabled the detection of one of the first cases of the OMICRON variant in mainland France.
Thierry Paper, Managing Director stated: “BIOSYNEX has invested heavily in the development of reliable and easy-to-use RT-PCR test solutions. The detection of a first case of the Omicron variant with our kit confirms the quality of our solutions and is a real source of satisfaction for the team. We are currently working to extend our range of molecular biology to support laboratories in their efforts to manage the Covid-19 pandemic.”
The second, LABPAD® Evolution is a portable in vitro diagnostic device. It allows numerous biological analyses to be carried out via a single reader, combined with a wide range of tests. More commonly used to measure INR, a coagulation index, LABPAD® technology can now be applied to quantitative serological tests and monitor patients’ levels of antibodies against Covid-19. Beyond its analytical and test recognition capabilities, the LabPad is fully connected and transmits the results automatically. A fast and secure care pathway thanks to end-to-end traceability of the test, with a practical application to check the level of antibodies against Covid-19 and adapt the vaccination schedule.
Dr Thomas LAMY, International Managing Director stated: “The international department has become one of the pillars of our company. Today, we cover more than 70 countries worldwide, from Latin America to Asia, via Europe, the Middle East and Africa. Our goal over the next 2 years is to strengthen our current position and open operations in over 100 countries. To promote its activities BIOSYNEX will be present again this year at the Arab Health exhibition, the leading international meeting place for the healthcare sector in the United Arab Emirates. This year we will be exhibiting at the France pavilion, in the Sheikh Saeed Hall on booth Z2D30.”
-Ends-
About Biosynex Group
Founded in 2005, the Biosynex group develops, manufactures and markets medical devices for screening, diagnosis and prevention. It has demonstrated its expertise by adapting to current health problems and exports its products worldwide. Its technological expertise focuses on the development of rapid diagnostic tests based on the principle of immunochromatography or immunofiltration as well as molecular biology. The various tests developed by Biosynex combine simplicity of execution, rapid results and a high level of clinical performance.
Additional information:
Yen-vy NGUYEN
Regional Project Leader
Yen-vy.nguyen@biosynex.com
Tel.: +33 781 882 533
Yasmina Ouari
Press Officer
yasmina.ouari@businessfrance.fr
https://www.biosynex.com/en/
© Press Release 2022
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
